PHARMANUTRAPHARMANUTRAPHARMANUTRA

PHARMANUTRA

No trades
See on Supercharts
Market capitalization
‪520.84 M‬EUR
‪12.83 M‬EUR
‪100.20 M‬EUR
‪3.12 M‬
Beta (1Y)
0.70

About PHARMANUTRA

CEO
Andrea Lacorte
Headquarters
Pisa
Employees (FY)
105
Founded
2003
ISIN
IT0005274094
FIGI
BBG00H5FW2L0
Pharmanutra SpA develops nutraceutical products and medical devices. Its Sroscaloidal Iron intends to restore articular and movement ability in osteoarticular affections, consisting of cetilar line. The company was founded by Andrea Lacorte and Roberto Lacorte in 2003 and is headquartered in Pisa, Italy.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of PHN is 53.0 EUR — it has decreased by 1.49% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange PHARMANUTRA stocks are traded under the ticker PHN.
PHARMANUTRA is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
PHN stock is 2.09% volatile and has beta coefficient of 0.70. Check out the list of the most volatile stocks — is PHARMANUTRA there?
One year price forecast for PHARMANUTRA has a max estimate of 86.0 EUR and a min estimate of 77.0 EUR.
PHN earnings for the last quarter are 0.23 EUR whereas the estimation was 0.23 EUR which accounts for 0% surprise. Estimated earnings for the next quarter are 0.40 EUR. See more details about PHARMANUTRA earnings.
PHARMANUTRA revenue for the last quarter amounts to ‪22.50 M‬ EUR despite the estimated figure of ‪22.50 M‬ EUR. In the next quarter revenue is expected to reach ‪26.50 M‬ EUR.
Yes, you can track PHARMANUTRA financials in yearly and quarterly reports right on TradingView.
PHN stock has fallen by 1.85% compared to the previous week, the month change is a 11.81% fall, over the last year PHARMANUTRA has showed a 1.67% decrease.
PHN net income for the last quarter is ‪3.10 M‬ EUR, while the quarter before that showed ‪2.50 M‬ EUR of net income which accounts for 24.09% change. Track more PHARMANUTRA financial stats to get the full picture.
Today PHARMANUTRA has the market capitalization of ‪517.29 M‬, it has decreased by 2.30% over the last week.
Yes, PHN dividends are paid annually. The last dividend per share was 0.80 EUR. As of today, Dividend Yield (TTM)% is 1.49%. Tracking PHARMANUTRA dividends might help you take more informed decisions.
PHARMANUTRA dividend yield was 1.51% in 2023, and payout ratio reached 64.04%. The year before the numbers were 1.28% and 51.42% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, PHN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHARMANUTRA stock right from TradingView charts — choose your broker and connect to your account.
PHN reached its all-time high on Jan 5, 2022 with the price of 80.0 EUR, and its all-time low was 12.0 EUR and was reached on Oct 2, 2017.
See other stocks reaching their highest and lowest prices.
As of Apr 18, 2024, the company has 105.00 employees. See our rating of the largest employees — is PHARMANUTRA on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PHARMANUTRA technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PHARMANUTRA stock shows the sell signal. See more of PHARMANUTRA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on PHARMANUTRA future price: according to them, PHN price has a max estimate of 86.00 EUR and a min estimate of 77.00 EUR. Read a more detailed PHARMANUTRA forecast: see what analysts think of PHARMANUTRA and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHARMANUTRA EBITDA is ‪22.52 M‬ EUR, and current EBITDA margin is 24.80%. See more stats in PHARMANUTRA financial statements.